{
    "nctId": "NCT05528133",
    "briefTitle": "Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer",
    "officialTitle": "Phase II Study of Genomically Guided Radiation Dose Personalization in the Management of Triple Negative Breast Cancer",
    "overallStatus": "RECRUITING",
    "conditions": "Triple Negative Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 86,
    "primaryOutcomeMeasure": "Local Control",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants should have undergone breast conservation therapy with a lumpectomy and axillary evaluation to consist of a sentinel node biopsy or axillary dissection\n* Confirmation of Triple Negative (TN) breast cancer by tissue biopsy\n* Adequate tissue to calculate RSI\n* To fulfill the requirement of HER2- disease, a breast cancer must not demonstrate, at initial diagnosis or upon subsequent biopsy, overexpression of HER2 by either IHC or in-situ hybridization as defined by the ASCO / CAP Guidelines\n* To fulfill the requirement of hormone receptor (HR)- disease, a breast cancer must express (\\<10%), by immunohistochemistry (IHC), the hormone receptors (estrogen receptor \\[ER\\] and progesterone receptor \\[PR\\]) as defined in the American Society of Clinical Oncology (ASCO) / College of American Pathologists (CAP) Guidelines\n* Life expectancy \\>16 weeks\n* KPS \u2265 70\n* Age \u2265 18 years\n* Participants with surgery within 14 days should have recovered from all effects of the surgery and be cleared by their surgeon\n* There is no limit on prior systemic therapies\n* Women of childbearing potential and sexually active males must commit to the use of effective contraception while on study\n* Ability to sign an informed consent form, which can be signed by a family member or health care proxy. Informed consent must be given before study enrollment\n\nExclusion Criteria:\n\n* Major surgery or significant traumatic injury that has not been recovered from 14 days before study initiation\n* Women who are pregnant or breastfeeding\n* Positive surgical margins\n* History of allergy or hypersensitivity to any of the study drugs or study drug components\n* Metastatic breast cancer",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}